Influence of blood glucose fluctuations on chemotherapy efficacy and safety in type 2 diabetes mellitus patients complicated with lung carcinoma

Table 1 Comparison of glycemic fluctuation indices after chemotherapy

	MAGE (mmol/L)	MODD (mmol/L)	LAGE (mmol/L)	SDBG (mmol/L)
Control group (n = 30)	3.75 ± 1.07	2.06 ± 0.36	4.25 ± 0.90	2.13 ± 0.33
Observation group (n = 30)	5.61 ± 1.15	2.59 ± 0.51	6.31 ± 1.21	2.72 ± 0.40
t value	6.451	4.721	7.472	6.195
P value	< 0.0001	< 0.0001	< 0.0001	< 0.0001

MAGE: Mean amplitude of glycemic excursions; MODD: Mean of daily differences; LAGE: Largest amplitude of glycemic excursions; SDBG: Standard deviation of blood glucose.

Table 2 Comparison of tumor markers after chemotherapy

	CA19-9 (U/mL)	CA125 (U/mL)	CEA (mg/L)	NSE (mg/L)	CYFRA21-1 (mg/L)
Control group (n = 30)	64.26 ± 5.20	65.27 ± 6.60	12.12 ± 2.11	15.97 ± 1.34	4.98 ± 0.82
Observation group (n = 30)	75.00 ± 9.48	83.72 ± 6.06	17.83 ± 2.28	19.86 ± 1.42	7.54 ± 0.96
t value	5.444	11.28	10.08	10.88	11.11
P value	< 0.0001	< 0.0001	< 0.0001	< 0.0001	< 0.0001

CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; NSE: Neuron-specific enolase; CYFRA21-1: Cytokeratin 19.

Table 3 Incidence of adverse reactions in the two groups of patients, n (%)

	Phlebitis	Gastrointestinal reactions	Oral ulcers	Liver and kidney dysfunction
Control group (n = 30)	3 (10.0)	6 (20.0)	4 (13.3)	2 (6.7)
Observation group (n = 30)	10 (33.3)	15 (50.0)	11 (36.7)	8 (26.7)
t value	4.8121	5.9341	4.3561	4.3201
P value	0.0283	0.0149	0.0369	0.0377